| Active substance | Rizatriptan |
|---|---|
| Chemical name | N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine |
| Side effects | Dizziness, drowsiness, fatigue, nausea, dry mouth, chest pain |
| Effects | Relief from migraine headaches |
| Dosage (sports) | Not applicable |
| Dosage (medical) | 5 mg or 10 mg tablets, typically at the onset of migraine symptoms, may repeat dose after 2 hours if needed, not to exceed 30 mg in a 24-hour period |
| Half-life | 2-3 hours |
| Main action | Serotonin receptor agonist |
| Substance class | Triptan |
| Formula | C15H19N5 |
| Storage conditions | Store at 15-30В°C (59-86В°F), keep away from moisture and light |
| Trade name | Maxalt |
| Blood pressure | Can cause transient increases |
| Also known as | Rizatriptan benzoate |
| Strength | 10mg |
| Lab Test | Not routinely required |
| Hepatotoxicity | Low |
| Water Retention | Minimal to none |
| Use in sports | None |
| Manufacturer | Cipla Ltd. |
| Packing | 4 tabs/blister |
Rizact 10 mg Cipla
€80.00
There are no reviews yet.